HSBC set a €87.00 ($101.16) target price on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research report released on Wednesday. The firm currently has a buy rating on the stock.

A number of other brokerages have also issued reports on FME. UBS Group set a €86.00 ($100.00) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a neutral rating in a research note on Wednesday, October 17th. Goldman Sachs Group set a €98.00 ($113.95) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research note on Wednesday, October 17th. Kepler Capital Markets set a €100.00 ($116.28) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research note on Thursday, October 18th. Barclays set a €87.20 ($101.40) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a neutral rating in a research note on Wednesday, October 17th. Finally, Nord/LB set a €85.00 ($98.84) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research note on Wednesday, October 17th. Nine research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company has an average rating of Buy and a consensus price target of €82.75 ($96.22).

Shares of FME stock opened at €68.50 ($79.65) on Wednesday. Fresenius Medical Care AG & Co. KGaA has a 12 month low of €75.53 ($87.83) and a 12 month high of €93.82 ($109.09).

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

See Also: Quiet Period

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.